Clayton Associates is a Nashville-based family office that makes seed to early-stage investments in healthcare and technology companies in the United States. Founded in 1996, it concentrates on healthcare technology, digital health, information technology, software, and technology-enabled services, and favors opportunities in the Southeast and Southwest United States. The firm typically makes equity investments ranging from about 0.5 million to 6 million, with enterprise values of 3 million to 15 million, and can participate in seed rounds of up to 0.5 million. It seeks minority stakes of roughly 20% to 40% and also engages in angel investments. Clayton Associates works through affiliates and partnerships, including Bullpen Ventures and Rolling Hills Ventures, via its venture-capital manager FCA Venture Partners. The firm is based in Brentwood and Nashville, Tennessee, with a history of supporting entrepreneurs and building growth in the healthcare and technology sectors.
Founded in 2006, AdhereHealth specializes in medication therapy management (MTM) services. It offers advanced solutions such as configured MTM programs, Star Solutions for enhancing CMS ratings, and Adhere platform for analytics-driven care gap resolution. The company serves patients, employers, health plans, physicians, and pharmacists, aiming to improve medication adherence and clinical outcomes.
CeloNova
Venture Round in 2003
CeloNova BioSciences, Inc., headquartered in San Antonio, Texas, is a global medical device company that develops, manufactures and markets a family of Interventional Cardiology and Endovascular products. Our products are developed and manufactured in California, U.S.A. and Germany. The Company’s regional offices are located in Germany, France, United Kingdom, Netherlands and Austria. CeloNova’s Interventional Cardiology and Endovascular products are currently available in more than fifty countries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.